Discussing Genitourinary (GU) Cancers ASCO 2022 Practice changing studies with Dr. Shilpa Gupta, Director of Taussig Cancer Institute and Co-Leader GU Onc, Cleveland Clinic GU Malignancy. Tags: Dr. Shilpa Gupta (GU) ASCO 2022 Genitourinary Share this: Related posts Conferences ASCO 2025 ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA Jul 04, 2025 Conferences ASCO 2025 ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04 Jun 20, 2025 You might be interested in ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04 Jun 14, 2025 ASCO 2025 Lung Cancer Highlights: CheckMate 816, ToD, NeoADAURA, IMforte, DeLLphi 304 Jun 07, 2025
Conferences ASCO 2025 ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA Jul 04, 2025
Conferences ASCO 2025 ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04 Jun 20, 2025